Clinicopathological features of hepatoid adenocarcinoma and non‐hepatoid adenocarcinoma of the stomach: A systematic review and meta‐analysis

Author:

Ling Qi1,Liu Han‐Lin2,Huang Shi‐Ting1,Sun Li‐Fei34,Wu Wei‐Wei5,Kudriashov Valentin1,Liu Kai1,Yang Kun1ORCID,Hu Jian‐Kun1ORCID,Zhang Wei‐Han1ORCID

Affiliation:

1. Department of General Surgery, Gastric Cancer Center West China Hospital, Sichuan University Chengdu Sichuan China

2. West China School of Medicine, Sichuan University Chengdu Sichuan China

3. Department of Obstetrics and Gynecology West China Second University Hospital of Sichuan University Chengdu Sichuan China

4. Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education Chengdu Sichuan China

5. Department of Anesthesiology West China Hospital, Sichuan University Chengdu Sichuan China

Abstract

AbstractBackgroundHepatoid adenocarcinoma of the stomach (HAS) is an extremely rare and unique malignant gastric tumor with a significantly worse prognosis than non‐hepatoid adenocarcinoma of the stomach (non‐HAS). The present study explored the clinicopathological features of HAS and non‐HAS patients to provide insights into HAS treatment strategies.MethodsFrom December 26, 2023, we performed a comprehensive search of the PubMed, Web of Science, Cochrane Library, and Embase.com databases for relevant studies. Two authors independently screened the studies, evaluated their quality, extracted data, and performed the analyses. This study was registered with PROSPERO on January 2, 2024.ResultsNine retrospective studies were included for analysis after screening 833 articles. A total of 350 and 924 patients were enrolled in the HAS and non‐HAS groups, respectively. While no significant differences were observed in age, sex, tumor size, T3 or T4 stage, and N2 or N3 stage between the two groups, the HAS group exhibited higher rates of lymph node metastasis (OR = 1.93, 95% CI: 1.19–3.13, p = 0.007), liver metastasis (OR = 3.45, 95% CI: 2.26–5.28, p < 0.001), and vascular invasion (OR = 2.76, 95% CI: 2.05–3.71, p < 0.001). Additionally, the HAS group had lower 3‐year survival rates (HR = 2.35, 95% CI: 1.70–3.25, p < 0.001) and 5‐year survival rates (HR = 3.63, 95% CI: 1.49–8.88, p = 0.005), but lower rates of lymphatic permeation (OR = 0.68, 95% CI: 0.47–0.99, p = 0.040).ConclusionBased on the current clinical evidence, patients with HAS present distinct clinicopathological features, greater invasiveness, and poorer prognosis than non‐HAS patients. Further research is warranted to develop optimal treatment strategies for HAS.

Funder

Natural Science Foundation of Sichuan Province

Publisher

Wiley

Reference44 articles.

1. An AFP-producing gastric carcinoma with features of hepatic differentiation. A case report

2. Hepatoid Adenocarcinoma of the Stomach: Current Perspectives and New Developments

3. Hepatoid Adenocarcinoma of the Duodenum: An Unusual Location

4. A case of AFP‐producing esophagogastric junction cancer with liver metastases with a good response to chemotherapy;Nagai Y;Gan To Kagaku Ryoho,2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3